Incyte (INCY) Income from Continuing Operations (2010 - 2026)
Incyte (INCY) reported Income from Continuing Operations of 303330000.0 for Q1 2026, up 91.73% on a YoY basis from 158203000.0 in Q1 2025, and up 1.35% quarter-over-quarter from 299279000.0 in Q4 2025.
Incyte (INCY) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Incyte has reported Income from Continuing Operations for 17 years, with the latest figure at 303330000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 91.73% year-over-year to 303330000.0; the trailing twelve-month figure through Mar 2026 stood at 1431777000.0 (up 6631.44% YoY), and the FY2025 full-year result was 1286650000.0, up 3844.96% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 303330000.0, up from 299279000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 424169000.0 in Q3 2025, with the low at 444601000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 150638470.59 across 5 years, with a median of 169548000.0 in 2024.
- The largest YoY upside for Income from Continuing Operations was 681.22% in 2024 against a maximum downside of 318.43% in 2024.
- Incyte's Income from Continuing Operations stood at 28461000.0 in 2022, then jumped by 606.51% to 201079000.0 in 2023, then climbed by 0.07% to 201212000.0 in 2024, then surged by 48.74% to 299279000.0 in 2025, then grew by 1.35% to 303330000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 303330000.0 (Q1 2026), 299279000.0 (Q4 2025), and 424169000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 303.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.85 Mn |
| Sep 30, 2021 | 181.77 Mn |
| Jun 30, 2021 | 149.46 Mn |